Liver Transplant Clinical Trial
Official title:
"Early Versus Routine Drain Removal After Live Liver Donor Hepatectomy- a Randomized Controlled, Open Label, Pilot Study".
Verified date | January 2022 |
Source | Institute of Liver and Biliary Sciences, India |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
It's a randomized control trial to compare early drain removal versus standard drain removal after donor hepatectomy in terms of donor outcomes. We will analyse the data and elucidate the safety of early drain removal using 3x3 rule with routine drain removal.
Status | Completed |
Enrollment | 108 |
Est. completion date | February 25, 2022 |
Est. primary completion date | February 25, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - • Donors evaluated as per institutional protocol for donor hepatectomy and found fit - Those who consent Exclusion Criteria: - Patients refusing to consent for inclusion in the study. - Left lateral hepatectomy. |
Country | Name | City | State |
---|---|---|---|
India | ILBS - Parthiban | Delhi |
Lead Sponsor | Collaborator |
---|---|
Institute of Liver and Biliary Sciences, India |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | safety of drain removal using 3x3 rule - overall complications. | Comprehensive complication index (CCI) - clavin dindo classification | patient will be followed upto 3 months after surgery | |
Secondary | Post operative pain relief | using Visual analogue score | patient will be followed upto 3 months after surgery | |
Secondary | Bile leak | standard ISGLS definition - drain bilirubin measured in mg/dl. | patient will be followed upto 3 months after surgery | |
Secondary | Length of hospital stay | calculated from the day of admission to day of discharge, and based on the number of nights spent in hospital | patient will be followed upto 3 months after surgery | |
Secondary | Surgical Site Infection (SSI) | patient has at least one of the following:
purulent drainage from the superficial incision. organism(s) identified from an aseptically-obtained specimen from the superficial incision or subcutaneous tissue by a culture or non-culture based microbiologic testing method which is performed for purposes of clinical diagnosis or treatment (for example, not Active Surveillance Culture/Testing (ASC/AST)). superficial incision that is deliberately opened by a surgeon, physician* or physician designee and culture or non-culture based testing of the superficial incision or subcutaneous tissue is not performed AND patient has at least one of the following signs or symptoms: localized pain or tenderness; localized swelling; erythema; or heat. diagnosis of a superficial incisional SSI by a physician* or physician designee. |
patient will be followed upto 3 months after surgery | |
Secondary | reintervention rate | defined as any additional abdominal intervention ( surgical or radiological) during the same hospital stay after the primary operation | patient will be followed upto 3 months after surgery | |
Secondary | readmission rate | 90 day readmission rate - any hospital admission after the index admission. | patient will be followed upto 3 months after surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02798861 -
Controlled Attenuation Parameter (CAP) in Liver Allografts
|
||
Completed |
NCT03527238 -
Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
|
Phase 2 | |
Completed |
NCT01696331 -
Text Messaging for Adherence in Adolescent Liver Transplant Recipients
|
N/A | |
Recruiting |
NCT05051605 -
Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation
|
||
Recruiting |
NCT05940857 -
Sponsor-Initiated OCS Liver Perfusion (OLP-II) Registry
|
||
Completed |
NCT01598987 -
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
|
Phase 3 | |
Active, not recruiting |
NCT05074160 -
OCS Liver Perfusion (OLP) Post-Approval Registry
|
||
Completed |
NCT05087550 -
Multicenter Study on Organ Acquisition Costs in the Post Re-Allocation Era: Liver Transplantation
|
||
Recruiting |
NCT04836923 -
LIFT Intervention in Liver Transplant Candidates
|
N/A | |
Not yet recruiting |
NCT03666689 -
Outflow Reconstruction in Right Lobe Living Donor Liver Transplantation
|
||
Not yet recruiting |
NCT06088758 -
Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool
|
N/A | |
Terminated |
NCT01230502 -
Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
|
N/A | |
Completed |
NCT00171509 -
Efficacy and Safety of Cyclosporine Microemulsion Given Once a Day in Adult Stable Liver Transplant Recipients
|
Phase 4 | |
Not yet recruiting |
NCT06254248 -
Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma
|
Phase 2 | |
Recruiting |
NCT06075745 -
Cytomegalovirus (CMV) Vaccine in Orthotopic Liver Transplant Candidates
|
Phase 2 | |
Completed |
NCT02057484 -
A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant
|
||
Active, not recruiting |
NCT03577431 -
Liver Transplantation With Tregs at MGH
|
Phase 1/Phase 2 | |
Recruiting |
NCT06342557 -
Transitional ePRO Diary Liver
|
||
Not yet recruiting |
NCT04265157 -
Hepato-duodenal Ligament Occlusion and Classic Technique in Liver Transplant
|
||
Recruiting |
NCT02863250 -
Australian and New Zealand Massive Transfusion Registry
|